Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026Business Wire • 03/17/26
Exact Sciences (EXAS) is a Top-Ranked Momentum Stock: Should You Buy?Zacks Investment Research • 03/11/26
Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive YearBusiness Wire • 03/04/26
Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry CollaborationBusiness Wire • 03/03/26
Exact Sciences Q4 Earnings Match Estimates, Revenues Beat, Stock UpZacks Investment Research • 02/19/26
Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences' '746 PatentBusiness Wire • 02/06/26
Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection TestsBusiness Wire • 02/03/26
Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients WorldwideBusiness Wire • 02/03/26
Small-Cap Growth Without Dividends: What NUSC's 1.4 Beta Really Costs Investors24/7 Wall Street • 01/22/26
Exact Sciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXASPRNewsWire • 01/16/26
Exact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie & Holleman LLP Regarding Potential ClaimsGlobeNewsWire • 12/30/25